Document 0835
 DOCN  M9650835
 TI    Primary central nervous system lymphoma.
 DT    9605
 AU    Freilich RJ; DeAngelis LM; Department of Neurology, Memorial
       Sloan-Kettering Cancer Center,; New York, New York, USA.
 SO    Neurol Clin. 1995 Nov;13(4):901-14. Unique Identifier : AIDSLINE
       MED/96157925
 AB    The rising incidence of PCNSL has allowed a greater understanding of the
       clinical features and behavior of this once rare tumor. Factors such as
       dissemination of tumor within the central nervous system, the presence
       of tumor behind an intact blood-brain barrier, as well as leptomeningeal
       and ocular involvement must be considered in the design of treatment
       protocols for this disease. The addition of chemotherapy has made a
       significant impact on the treatment of PCNSL, but the prognosis of PCNSL
       remains worse than for comparable systemic non-Hodgkin's lymphomas. With
       continued development of chemotherapy regimens, the hope is for improved
       survival without the need for potentially neurotoxic radiation therapy.
 DE    Brain/PATHOLOGY  Brain Neoplasms/PATHOLOGY/*THERAPY  Chemotherapy,
       Adjuvant  Combined Modality Therapy  Cranial Irradiation  Human
       Lymphoma, AIDS-Related/PATHOLOGY/*THERAPY  Lymphoma,
       Non-Hodgkin's/PATHOLOGY/*THERAPY  Prognosis  JOURNAL ARTICLE  REVIEW
       REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).